The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Changes in cardiovascular signaling proteins during doxorubicin treatment in children with high-risk ALL.
T. L. Miller
No relevant relationships to disclose
S. E. Lipshultz
No relevant relationships to disclose
R. E. Scully
No relevant relationships to disclose
D. Sawyer
No relevant relationships to disclose
S. R. Lipsitz
No relevant relationships to disclose
L. B. Silverman
No relevant relationships to disclose
H. Smith
No relevant relationships to disclose
J. M. Henkel
No relevant relationships to disclose
V. I. Franco
No relevant relationships to disclose
L. L. Cushman
No relevant relationships to disclose
S. E. Sallan
No relevant relationships to disclose